<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Case Rep Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Case Rep Psychiatry</journal-id><journal-id journal-id-type="publisher-id">CRIM.PSYCHIATRY</journal-id><journal-title-group><journal-title>Case Reports in Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">2090-682X</issn><issn pub-type="epub">2090-6838</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22937411</article-id><article-id pub-id-type="pmc">3420713</article-id><article-id pub-id-type="doi">10.1155/2011/846489</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Addition of Aripiprazole to the Clozapine May Be Useful in Reducing Anxiety in Treatment-Resistant Schizophrenia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chanachev</surname><given-names>Aleksandar</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Ansermot</surname><given-names>Nicolas</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Crettol Wavre</surname><given-names>S&#x000e9;verine</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nowotka</surname><given-names>Ute</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Stamatopoulou</surname><given-names>Maria-Eleni</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Conus</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Eap</surname><given-names>Chin B.</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Psychiatry, Centre Hospitalier Universitaire Vaudois, Section Eugene Minkowski, Site de Cery, 1008 Prilly, Switzerland</aff><aff id="I2"><sup>2</sup>Unit&#x000e9; de Biochimie et Psychopharmacologie Clinique, Centre de Neurosciences Psychiatriques, Site de Cery, 1008 Prilly, Switzerland</aff><aff id="I3"><sup>3</sup>Department of Psychiatry, Centre Hospitalier Universitaire Vaudois, Psychiatrie de Liason-Urgences et Crise, 1011 Lausanne, Switzerland</aff><author-notes><corresp id="cor1">*Aleksandar Chanachev: <email>aleksandar.chanachev@chuv.ch</email></corresp><fn fn-type="other"><p>Academic Editors: J. S. Brar and Y. Kaneda</p></fn></author-notes><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub"><day>14</day><month>9</month><year>2011</year></pub-date><volume>2011</volume><elocation-id>846489</elocation-id><history><date date-type="received"><day>23</day><month>6</month><year>2011</year></date><date date-type="accepted"><day>11</day><month>7</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011 Aleksandar Chanachev et al.</copyright-statement><copyright-year>2011</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>There exist many case reports and studies on the antipsychotic augmentation by aripirazole in partial responders to clozapine, the most seem to be finding a slight difference in the PANSS and CGI scores after the aripirazole addition. The results of our report are compatible with those of other studies but, we have found a considerable antianxiety action in both of the cases. The 5HT1A agonism of aripirazole could be hypothesized as mechanism contributing to this effect.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Clozapine is the drug of choice in treatment-resistant schizophrenia, but 40&#x02013;70% of clozapine-treated patients continue to demonstrate suboptimal clinical response [<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>]. </p><p>Various augmentation strategies have been tested, including the use of other atypical antipsychotics, but no clear recommendations can presently be proposed [<xref ref-type="bibr" rid="B5">5</xref>&#x02013;<xref ref-type="bibr" rid="B10">10</xref>]. </p><p>Augmentation with aripiprazole has been documented in case reports [<xref ref-type="bibr" rid="B11">11</xref>], in open trials [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B12">12</xref>], and in a randomized controlled study [<xref ref-type="bibr" rid="B13">13</xref>].</p><p>In this paper, we report on 2 cases in which augmentation with aripiprazole had a beneficial impact on anxiety.</p></sec><sec id="sec2"><title>2. Case Presentation</title><sec sec-type="subsection" id="sec2.1"><title>2.1. Case Report 1</title><p>Ms. A, a 40-year-old woman diagnosed with a residual schizophrenia [<xref ref-type="bibr" rid="B14">14</xref>] was admitted following an exacerbation of psychotic symptoms with a predominance of anxiety despite 700&#x02009;mg/d of clozapine for two years. The clinical scores and the trough plasma concentrations of clozapine and norclozapine at admission were CGI&#x02009;:&#x02009;5; total PANSS: 123; positive: 17/49; negative: 18/49; excited component: 12/35; general: 39/112; Hamilton-anxiety: 14/56; clozapine: 896&#x02009;ng/mL; norclozapine: 551&#x02009;ng/mL, respectively (clozapine therapeutic range: 350&#x02013;600&#x02009;ng/mL [<xref ref-type="bibr" rid="B15">15</xref>&#x02013;<xref ref-type="bibr" rid="B17">17</xref>]). Because of the risks of seizures, the dose was reduced to 500&#x02009;mg/d, and aripiprazole (10&#x02009;mg/d) was added. Clozapine and norclozapine plasma concentrations measured after 10 days were decreased according to the reduction of the dose (615&#x02009;ng/mL and 478&#x02009;ng/mL, resp.). The aripiprazole plasma concentration after 10 days was 282&#x02009;ng/mL. Following a clinical reduction of the anxiety, the patient was discharged from the hospital three weeks after the addition of aripiprazole.</p><p>A followup over 6 months did not reveal any change in the CGI and PANSS scores (at 6 months: CGI&#x02009;:&#x02009;5; total PANSS: 125; positive: 18/49; negative: 23/49; excited component 10/35; general: 38/112). On the other hand, the Hamilton-anxiety score diminished progressively to 12, 7, and 8 after one, three, and 6 months, respectively. Clozapine and norclozapine plasma levels were stable over this period (at the sixth month: 608&#x02009;ng/mL, 443&#x02009;ng/mL, and 75&#x02009;kg, resp.), and the comedications (clorazepate 20&#x02009;mg/d, valsartane 40&#x02009;mg/d, zopiclone 7,5&#x02009;mg/d, and tamsulosine 0.4&#x02009;mg/d) were not modified. No reports are describing an impact on anxiety by the antihypertensive comedication by valsartane (an angiotensin II receptor antagonist) and tamsulosine (peripheral <italic>&#x003b1;</italic>1-antagonist). There is no significant pharmacokinetic or pharmacodynamic interactions of that comedication and the antipsychotic/anxiolytic treatments.</p></sec><sec sec-type="subsection" id="sec2.2"><title>2.2. Case Report 2</title><p>Mr. L, a 48-year-old man with a diagnosis of residual schizophrenia [<xref ref-type="bibr" rid="B14">14</xref>] treated for many years with clozapine 500&#x02009;mg/d was admitted because of the worsening of his anxiety. The clinical scores and the trough plasma concentrations of clozapine and norclozapine were: CGI&#x02009;:&#x02009;4; total PANSS: 88; positive: 20/49; negative 25/49; excited component: 9/35; general 40/112. Hamilton-anxiety: 24/56; clozapine: 594&#x02009;ng/mL; norclozapine: 470&#x02009;ng/mL, respectively. Aripiprazole 10&#x02009;mg/d was added to clozapine (dose unchanged) and lorazepam (1&#x02009;mg/d) was discontinued. The patient was discharged three weeks after the aripiprazole addition.</p><p>A followup over 3 months did not reveal any change in the CGI and PANSS scores (at 3 months: CGI&#x02009;:&#x02009;4; total PANSS: 73; positive: 20/49; negative: 25/49; excited component: 7/35; general: 40/112), while the Hamilton-anxiety score diminished progressively to 19 and 15 after one and three months, respectively. The clozapine and norclozapine plasma concentrations at three months were 431&#x02009;ng/mL and 343&#x02009;ng/mL, respectively.</p></sec></sec><sec id="sec3"><title>3. Discussion</title><p>In the present paper the augmentation did not result in a reduction of psychotic symptoms despite a treatment period of 3 to 6 months, which is in agreement with previous reports [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B10">10</xref>&#x02013;<xref ref-type="bibr" rid="B13">13</xref>]. Because a therapeutic window has been demonstrated for clozapine [<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>], it is important to mention that therapeutic blood levels of clozapine were maintained during the whole observation period. An important reduction of anxiety was clinically observed in both cases, with a marked improvement of psychosocial functioning observed, which allowed a change of residential institution of both cases, three and six months after the discharge from the hospital, for a residential stay in more open environment with less psychosocial accompanying measures. </p><p>It has been suggested that in anxiety disorders, the adjunction of atypical antipsychotics to the current SSRI and/or benzodiazepine treatment could, through the modulation of the dopaminergic system, be beneficial but the data are not conclusive [<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>].</p><p>The agonist action of aripiprazole on the 5HT1A receptors could eventually contribute to the antianxiety action that we have observed [<xref ref-type="bibr" rid="B21">21</xref>].</p><p>However, considering the present observations could be due to external factors or to the natural evolution of the illness, a randomized controlled study is required to evaluate the efficacy of the clozapine-aripiprazole combination in cases of treatment-resistant schizophrenia with predominance of anxiety. Moreover, the anxiety observed in Case 1 could have been in part attributable to psychotoxic effects due to the high plasma concentration at the begining of the followup [<xref ref-type="bibr" rid="B22">22</xref>].</p></sec></body><back><ack><title>Disclosure</title><p>The authors attest that their research is not sponsored by any pharmaceutical companies, biomedical device manufacturers, or other corporation whose products or services may be related to the subject matter of the article and that they have no a financial relationship with this kind of commercial organizations.</p></ack><ack><title>Acknowledgments</title><p>P. Conus received an unrestricted educational grant for an investigator initiated trial from Bristol-Myers Squibb, and supports for attending conferences and/or giving speeches from Bristol-Myers Squibb, Janssen-Cilag, Eli Lily and Astra Zeneca. C. B. Eap received non-restricted educational grants for investigator initiated trials from Janssen-Cilag and Bristol-Myers Squibb. He received honoraria for conferences or teaching CME courses from Astra Zeneca, Bristol-Myers Squibb, Eli Lily, Essex Chemie, Glaxo-Smith Kline, Janssen-Cilag, Lundbeck, Novo Nordisk, and Organon.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kane</surname><given-names>J</given-names></name><name><surname>Honigfeld</surname><given-names>G</given-names></name><name><surname>Singer</surname><given-names>J</given-names></name><name><surname>Meltzer</surname><given-names>H</given-names></name></person-group><article-title>Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine</article-title><source><italic>Archives of General Psychiatry</italic></source><year>1988</year><volume>45</volume><issue>9</issue><fpage>789</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">3046553</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipriani</surname><given-names>A</given-names></name><name><surname>Boso</surname><given-names>M</given-names></name><name><surname>Barbui</surname><given-names>C</given-names></name></person-group><article-title>Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia</article-title><source><italic>Cochrane Database of Systematic Reviews</italic></source><year>2009</year><issue>3</issue><comment>Article ID CD006324.</comment></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conley</surname><given-names>RR</given-names></name><name><surname>Kelly</surname><given-names>DL</given-names></name></person-group><article-title>Management of treatment resistance in schizophrenia</article-title><source><italic>Biological Psychiatry</italic></source><year>2001</year><volume>50</volume><issue>11</issue><fpage>898</fpage><lpage>911</lpage><pub-id pub-id-type="pmid">11743944</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieberman</surname><given-names>JA</given-names></name><name><surname>Safferman</surname><given-names>AZ</given-names></name><name><surname>Pollack</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome</article-title><source><italic>American Journal of Psychiatry</italic></source><year>1994</year><volume>151</volume><issue>12</issue><fpage>1744</fpage><lpage>1752</lpage><pub-id pub-id-type="pmid">7977880</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitsonis</surname><given-names>CI</given-names></name><name><surname>Dimopoulos</surname><given-names>NP</given-names></name><name><surname>Mitropoulos</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: an open-label pilot study</article-title><source><italic>Progress in Neuro-Psychopharmacology and Biological Psychiatry</italic></source><year>2007</year><volume>31</volume><issue>2</issue><fpage>373</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">17092620</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouaffak</surname><given-names>F</given-names></name><name><surname>Tranulis</surname><given-names>C</given-names></name><name><surname>Gourevitch</surname><given-names>R</given-names></name><etal/></person-group><article-title>Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia</article-title><source><italic>Clinical Neuropharmacology</italic></source><year>2006</year><volume>29</volume><issue>1</issue><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">16518132</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Josiassen</surname><given-names>RC</given-names></name><name><surname>Joseph</surname><given-names>A</given-names></name><name><surname>Kohegyi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial</article-title><source><italic>American Journal of Psychiatry</italic></source><year>2005</year><volume>162</volume><issue>1</issue><fpage>130</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">15625211</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anil Yagcioglu</surname><given-names>AE</given-names></name><name><surname>Kivircik Akdede</surname><given-names>BB</given-names></name><name><surname>Turgut</surname><given-names>TI</given-names></name><etal/></person-group><article-title>A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety</article-title><source><italic>The Journal of clinical psychiatry</italic></source><year>2005</year><volume>66</volume><issue>1</issue><fpage>63</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">15669890</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honer</surname><given-names>WG</given-names></name><name><surname>Thornton</surname><given-names>AE</given-names></name><name><surname>Chen</surname><given-names>EYH</given-names></name><etal/></person-group><article-title>Clozapine alone versus clozapine and risperidone with refractory schizophrenia</article-title><source><italic>New England Journal of Medicine</italic></source><year>2006</year><volume>354</volume><issue>5</issue><fpage>472</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">16452559</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Remington</surname><given-names>G</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Elkis</surname><given-names>H</given-names></name><name><surname>Meltzer</surname><given-names>HY</given-names></name></person-group><article-title>Augmenting clozapine response in treatment-resistant schizophrenia</article-title><source><italic>Therapy-Resistant Schizophrenia</italic></source><year>2010</year><volume>26</volume><publisher-loc>Basel, Switzerland</publisher-loc><publisher-name>Karger</publisher-name><fpage>129</fpage><lpage>151</lpage><series>Advances in Biological Psychiatry</series></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karunakaran</surname><given-names>K</given-names></name><name><surname>Tungaraza</surname><given-names>TE</given-names></name><name><surname>Harborne</surname><given-names>GC</given-names></name></person-group><article-title>Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?</article-title><source><italic>Journal of Psychopharmacology</italic></source><year>2007</year><volume>21</volume><issue>4</issue><fpage>453</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">17050662</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>DC</given-names></name><name><surname>Kunkel</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>D</given-names></name><etal/></person-group><article-title>An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia</article-title><source><italic>Acta Psychiatrica Scandinavica</italic></source><year>2006</year><volume>113</volume><issue>2</issue><fpage>142</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">16423166</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>JS</given-names></name><name><surname>Ahn</surname><given-names>YM</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial</article-title><source><italic>Journal of Clinical Psychiatry</italic></source><year>2008</year><volume>69</volume><issue>5</issue><fpage>720</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">18370574</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="book"><collab>American Psychiatric Association</collab><source><italic>Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR</italic></source><year>2000</year><edition>4th edition</edition><publisher-name>American Psychiatric Publishing</publisher-name></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Guy</surname><given-names>W</given-names></name><etal/></person-group><source><italic>ECDEU Assessment Manual for Psychopharmacology</italic></source><year>1976</year><publisher-loc>Rockville, Md, USA</publisher-loc><publisher-name>U.S. Department of Helath, Education, and Welfare</publisher-name></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>SR</given-names></name><name><surname>Opler</surname><given-names>LA</given-names></name><name><surname>Fiszbein</surname><given-names>A</given-names></name></person-group><source><italic>Positive and Negative Syndrome Scale-Manual</italic></source><year>1992</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>Multi-Health Systems</publisher-name></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>P</given-names></name><name><surname>Hiemke</surname><given-names>C</given-names></name><name><surname>Ulrich</surname><given-names>S</given-names></name><etal/></person-group><article-title>The AGNP-TDM expert group consensus guidelines: therapeutic Drug Monitoring in psychiatry</article-title><source><italic>Pharmacopsychiatry</italic></source><year>2004</year><volume>37</volume><issue>6</issue><fpage>243</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">15551191</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>PJ</given-names></name><name><surname>Miller</surname><given-names>DD</given-names></name><name><surname>Arndt</surname><given-names>SV</given-names></name><name><surname>Cadoret</surname><given-names>RJ</given-names></name></person-group><article-title>Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients</article-title><source><italic>American Journal of Psychiatry</italic></source><year>1991</year><volume>148</volume><issue>2</issue><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="pmid">1670979</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>K</given-names></name><name><surname>Muzina</surname><given-names>D</given-names></name><name><surname>Gajwani</surname><given-names>P</given-names></name><name><surname>Calabrese</surname><given-names>JR</given-names></name></person-group><article-title>Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review</article-title><source><italic>Journal of Clinical Psychiatry</italic></source><year>2006</year><volume>67</volume><issue>9</issue><fpage>1327</fpage><lpage>1340</lpage><pub-id pub-id-type="pmid">17017818</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenz</surname><given-names>RA</given-names></name><name><surname>Jackson</surname><given-names>CW</given-names></name><name><surname>Saitz</surname><given-names>M</given-names></name></person-group><article-title>Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder</article-title><source><italic>Pharmacotherapy</italic></source><year>2010</year><volume>30</volume><issue>9</issue><fpage>942</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">20795849</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzman</surname><given-names>MA</given-names></name></person-group><article-title>Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness</article-title><source><italic>Journal of Affective Disorders</italic></source><year>2011</year><volume>128</volume><issue>supplement 1</issue><fpage>S11</fpage><lpage>S20</lpage><pub-id pub-id-type="pmid">21220076</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pallanti</surname><given-names>S</given-names></name><name><surname>Quercioli</surname><given-names>L</given-names></name><name><surname>Pazzagli</surname><given-names>A</given-names></name></person-group><article-title>Social anxiety and premorbid personality disorders in paranoid schizophrenic patients treated with clozapine</article-title><source><italic>CNS Spectrums</italic></source><year>2000</year><volume>5</volume><issue>9</issue><fpage>29</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">17637578</pub-id></element-citation></ref></ref-list></back></article>